Page 11 - Pfizer Global Product Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pfizer s (PFE) Elranatamab Granted FDA Breakthrough Therapy Designation

Pfizer s (PFE) Elranatamab Granted FDA Breakthrough Therapy Designation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomChris boshoffPfizer incAmerican society of hematology annual meetingEuropean medicines agencyDrug administrationPfizer global product developmentHealthcare products regulatory agencyBreakthrough therapy designationChief development officerRare diseasePfizer global productTherapy designationAmerican societyHematology annual meeting

Pfizer s Talzenna combination treatment meets primary endpoint in phase 3 prostate cancer study

Pfizer s Talzenna combination treatment meets primary endpoint in phase 3 prostate cancer study
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United statesChris boshoffPfizer global product developmentSouth america

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChris boshoffSuneet varmaDrug administrationPfizer global product developmentLab abnormalitiesExchange commissionPfizer incMedivation incWall streetChief development officerRare diseasePfizer global productGlobal oncologyPfizer oncologySouth america

Pfizer Reports Positive Topline Results From Phase 3 TALZENNA Trial

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced Tuesday positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib) plus XTANDI in men with metastatic castration-resistant

Chris boshoffPfizer incPfizer global product developmentMore such health newsChief development officerRare disease

FDA and EMA Accept Regulatory Submission for Pfizer s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata

FDA and EMA Accept Regulatory Submission for Pfizer s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMichael corboEuropean academy of dermatologyAmerican academy of dermatology annual meetingDrug administrationPfizer global product developmentExchange commissionPfizer incEuropean medicines agencyNew drug applicationMarketing authorization applicationChief development officerPfizer global productDermatology annualAlopecia tool